Coverage
-
April 20, 2020
Hospira Inc. has paid Amgen Inc. more than $70 million for infringing a patent covering its anemia treatment Epogen, after the Federal Circuit refused to grant Hospira any relief from a 2017 judgment.
13 other articles on this case.
View all »